Alumis公布Envudeucitinib治疗中重度斑块型银屑病三期数据，将于2026年AAD年会作重磅报告

美股速递

Mar 18

**关键临床数据即将揭晓** 生物制药公司Alumis Inc.宣布，其主打候选药物Envudeucitinib用于中重度斑块型银屑病治疗的三期临床试验数据，已被遴选为2026年美国皮肤病学会（AAD）年会的"迟来突破"口头报告环节。该环节专门展示具有高度临床价值的最新研究成果，意味着Envudeucitinib的三期数据获得了学术委员会对其科学重要性的认可。

**银屑病市场格局与竞争潜力** 斑块型银屑病作为自身免疫性皮肤病，全球患者群体庞大，现有治疗方案虽多但仍有未满足的临床需求。Envudeucitinib是一种口服TYK2抑制剂，其作用机制针对JAK-STAT信号通路中的特定靶点，理论上可能在疗效与安全性之间取得更好平衡。若三期数据积极，该药物有望在2026年AAD年会前后提交上市申请，切入规模可观的银屑病治疗市场。

**后续开发与市场影响** Alumis计划在2026年AAD年会上公布Envudeucitinib三期试验的详细疗效与安全性结果。这些数据将对公司估值产生直接影响，并可能引发大型药企的并购兴趣。投资界将密切关注该药物在疗效指标（如PASI 75/90/100应答率）及安全性特征（特别是感染、肝酶升高等风险）方面的表现，以评估其市场竞争力。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1104384434"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1104384434\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1104384434?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-18 20:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104384434","market":"us","top_or_hot":-1,"title":"Alumis公布Envudeucitinib治疗中重度斑块型银屑病三期数据，将于2026年AAD年会作重磅报告","media":"美股速递","content":"<p>**关键临床数据即将揭晓**\n生物制药公司Alumis Inc.宣布，其主打候选药物Envudeucitinib用于中重度斑块型银屑病治疗的三期临床试验数据，已被遴选为2026年美国皮肤病学会（AAD）年会的\"迟来突破\"口头报告环节。该环节专门展示具有高度临床价值的最新研究成果，意味着Envudeucitinib的三期数据获得了学术委员会对其科学重要性的认可。</p>\n<p>**银屑病市场格局与竞争潜力**\n斑块型银屑病作为自身免疫性皮肤病，全球患者群体庞大，现有治疗方案虽多但仍有未满足的临床需求。Envudeucitinib是一种口服TYK2抑制剂，其作用机制针对JAK-STAT信号通路中的特定靶点，理论上可能在疗效与安全性之间取得更好平衡。若三期数据积极，该药物有望在2026年AAD年会前后提交上市申请，切入规模可观的银屑病治疗市场。</p>\n<p>**后续开发与市场影响**\nAlumis计划在2026年AAD年会上公布Envudeucitinib三期试验的详细疗效与安全性结果。这些数据将对公司估值产生直接影响，并可能引发大型药企的并购兴趣。投资界将密切关注该药物在疗效指标（如PASI 75/90/100应答率）及安全性特征（特别是感染、肝酶升高等风险）方面的表现，以评估其市场竞争力。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alumis公布Envudeucitinib治疗中重度斑块型银屑病三期数据，将于2026年AAD年会作重磅报告</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlumis公布Envudeucitinib治疗中重度斑块型银屑病三期数据，将于2026年AAD年会作重磅报告\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1004306016\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">美股速递 </p>\n<p class=\"h-time\">2026-03-18 20:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>**关键临床数据即将揭晓**\n生物制药公司Alumis Inc.宣布，其主打候选药物Envudeucitinib用于中重度斑块型银屑病治疗的三期临床试验数据，已被遴选为2026年美国皮肤病学会（AAD）年会的\"迟来突破\"口头报告环节。该环节专门展示具有高度临床价值的最新研究成果，意味着Envudeucitinib的三期数据获得了学术委员会对其科学重要性的认可。</p>\n<p>**银屑病市场格局与竞争潜力**\n斑块型银屑病作为自身免疫性皮肤病，全球患者群体庞大，现有治疗方案虽多但仍有未满足的临床需求。Envudeucitinib是一种口服TYK2抑制剂，其作用机制针对JAK-STAT信号通路中的特定靶点，理论上可能在疗效与安全性之间取得更好平衡。若三期数据积极，该药物有望在2026年AAD年会前后提交上市申请，切入规模可观的银屑病治疗市场。</p>\n<p>**后续开发与市场影响**\nAlumis计划在2026年AAD年会上公布Envudeucitinib三期试验的详细疗效与安全性结果。这些数据将对公司估值产生直接影响，并可能引发大型药企的并购兴趣。投资界将密切关注该药物在疗效指标（如PASI 75/90/100应答率）及安全性特征（特别是感染、肝酶升高等风险）方面的表现，以评估其市场竞争力。</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1104384434","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104384434","pubTimestamp":1773835493,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"生物制药公司Alumis Inc.宣布，其主打候选药物Envudeucitinib用于中重度斑块型银屑病治疗的三期临床试验数据，已被遴选为2026年美国皮肤病学会年会的\"迟来突破\"口头报告环节。该环节专门展示具有高度临床价值的最新研究成果，意味着Envudeucitinib的三期数据获得了学术委员会对其科学重要性的认可。若三期数据积极，该药物有望在2026年AAD年会前后提交上市申请，切入规模可观的银屑病治疗市场。Alumis计划在2026年AAD年会上公布Envudeucitinib三期试验的详细疗效与安全性结果。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4007":"制药","ALMS":"Alumis Inc."},"translate_title":"Alumis announces phase III data of Envudeucitinib in the treatment of moderate to severe plaque psoriasis, and will make a blockbuster report at the 2026 AAD Annual Meeting","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALMS":1},"content_text":"**关键临床数据即将揭晓**\n生物制药公司Alumis Inc.宣布，其主打候选药物Envudeucitinib用于中重度斑块型银屑病治疗的三期临床试验数据，已被遴选为2026年美国皮肤病学会（AAD）年会的\"迟来突破\"口头报告环节。该环节专门展示具有高度临床价值的最新研究成果，意味着Envudeucitinib的三期数据获得了学术委员会对其科学重要性的认可。\n**银屑病市场格局与竞争潜力**\n斑块型银屑病作为自身免疫性皮肤病，全球患者群体庞大，现有治疗方案虽多但仍有未满足的临床需求。Envudeucitinib是一种口服TYK2抑制剂，其作用机制针对JAK-STAT信号通路中的特定靶点，理论上可能在疗效与安全性之间取得更好平衡。若三期数据积极，该药物有望在2026年AAD年会前后提交上市申请，切入规模可观的银屑病治疗市场。\n**后续开发与市场影响**\nAlumis计划在2026年AAD年会上公布Envudeucitinib三期试验的详细疗效与安全性结果。这些数据将对公司估值产生直接影响，并可能引发大型药企的并购兴趣。投资界将密切关注该药物在疗效指标（如PASI 75/90/100应答率）及安全性特征（特别是感染、肝酶升高等风险）方面的表现，以评估其市场竞争力。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"conferences,dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}